KOSLIV Secures Tens of Millions in Series A Funding from TianTu Investment, Launches Sub-brand 'LeTan 1389' to Pioneer Scalp Health Economy with 'Store-in-Store' Model

On June 6, 2026, the tech-driven hair care brand “KOSLIV” held the “Top Priority, Healthy China” 2026 Scalp Health Industry Inclusive Summit in Shenzhen, officially announcing the completion of its tens-of-millions-yuan Series A financing, exclusively invested by Tiantu Investment. At the same event, the company launched its sub-brand “LeTan 1389” and announced the initiation of the “1389 Scalp Health Project.” With capital backing secured and a new service brand implemented, this company, known for its strengths in technological R&D, has formally transitioned from a product-centric model to a new phase driven by the dual engines of “products + services.”

"KOSLIV“KOSLIV” was founded in 2019 and positions itself as a provider of full-cycle scalp care solutions. The brand’s English name is derived from Norwegian, meaning “to make life more comfortable and at ease.” However, a review of its development trajectory over the past few years reveals that the company has not taken the “comfortable” route; instead, it has chosen a more intensive path focused on technological research and development.

As of now, KOSLIV has obtained the certificates issued by the China National Intellectual Property Administration.Two core invention patents for “anti-hair loss” and “melanin promotion.” Among them, the anti-hair loss patented ingredient “Keshi Peptide” demonstrated outstanding performance in third-party testing: it upregulated the key follicular stem cell protein β-catenin by 37.84% and inhibited the inflammatory factor IL-6 by 34.83%, with both metrics outperforming the control drug minoxidil. The melanin-promoting patented ingredient “Keluowu” targets the underlying mechanisms of gray hair. By employing a dual-strain co-fermentation technology, it increased tyrosinase activity by 89.6%, melanin content by 130.7%, and antioxidant capacity by 94.8%. This signifies that the traditional “surface coverage” approach to gray hair care is being replaced by a technological pathway that activates melanocytes at the cellular level.

Whether technology can be successfully implemented often depends onthe critical step of “absorption.” KOSLIV’s solution was to partner with Professor Zhang Jiaheng’s team at Harbin Institute of Technology (Shenzhen) to introduce supramolecular penetration technology into the hair care sector, securing exclusive rights to use this technology in China. In simple terms, supramolecular solvents are used to “encapsulate” active ingredients for precise delivery deep into the hair follicles. National patent testing data show that the cumulative penetration of active ingredients increased more than fivefold after adopting this technology. At the summit’s roundtable forum, Professor Zhang Jiaheng described the significance of this technology as follows: “Supramolecular technology has transformed scalp care from ‘superficial treatment’ to ‘deep penetration,’ raising the technological benchmark for the entire industry.”

The scalp health market is expanding rapidly. Data from the National Health Commission shows that the number of people suffering from hair loss in China has exceededThe population with graying hair exceeds 420 million, and both groups are showing a clear trend toward younger demographics. Meanwhile, market supply has long been polarized: at one end are low-cost chemical hair dyes and products with conceptual additive claims; at the other are customized services with high price thresholds. “The middle ground is empty,” stated Han Juanjuan in her keynote speech at the summit. “KOSLIV serves as the technological source, while Le Tan 1389 provides inclusive solutions. The two are not differentiated by hierarchy but represent different customer-facing services powered by the same underlying technology platform.”

This statement highlights the core initiative of this summit.— The Launch of “Letan 1389.” Its model can be summarized as “a 3-square-meter pod, an 8-minute rapid follicle recharge, and a ‘hundred industries + shop-in-shop’ approach.” Standardized service pods are embedded in scenarios such as pharmacies, maternal and infant stores, and office buildings, enabling consumers to complete an AI scalp analysis and essence infusion treatment within eight minutes. Jing Xiaofeng, co-initiator of the Letan 1389 project, deconstructed this model in his speech: “Single-store investment is controllable, standardization is high, and AI diagnostic devices enable visualization of pre- and post-treatment data. Our goal is not to open more hair care salons, but to make scalp care a value-added module for other business formats.”

This model has currently been implemented in Shenzhen for over20 stores; provincial distributor agreements for Yunnan, Hainan, Jiangxi, Jiangsu, and Guangdong were signed at the summit. More than 50 additional stores are expected to open within the year, expanding coverage to more provinces and cities.

Li Kanglin, a partner at Tiantu Capital, stated during a roundtable discussion when asked about his investment logic that the scalp health sector is currently in“We are in an early stage characterized by high demand, scarce supply, and limited trust,” while the KOSLIV team possesses both technological barriers and implementation capabilities. “The consumer investment sector is not short of narratives; what it lacks are teams capable of turning patents into products and products into services. The logic behind what this team is doing is sound.”

Han Juanjuan stated,The Series A funding will be primarily allocated to continuous R&D, product upgrades, market expansion, and team building. “Securing the funding is not the end goal; the real priority is to complete the necessary R&D and establish the required distribution channels.”

It was also announced at the summit that KOSLIV has signed agreements with the Interpharm Research Institute of Anhui Medical University and Shanhai Innovation for joint R&D and the establishment of a collaborative laboratory. This deeper integration of industry, academia, and research may serve as the cornerstone for the company’s next phase of technological iteration.